# Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

> **NCT07188545** · — · ACTIVE_NOT_RECRUITING · sponsor: **Ohio State University** · enrollment: 23280000 (estimated)

## Conditions studied

- Cardiovascular Kidney Metabolic Syndrome

## Interventions

- **DRUG:** Intervention
- **DRUG:** Active Comparator

## Key facts

- **NCT ID:** NCT07188545
- **Lead sponsor:** Ohio State University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2029-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 23280000 (ESTIMATED)
- **Last updated:** 2025-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07188545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07188545, "Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07188545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*